Rituxan
Ailment: Rheumatoid Arthritis
U.S. Sales: $3.6 billion
Owner: Roche
Rituxan is administered via infusion in a doctor’s office and can provide up to six months of symptom-free living. Fifteen years after its introduction, sales of Rituxan remain strong, but the drug’s patent expires in 2018.
